Abstract
Adult mice were administered either the noradrenaline (NA) neurotoxin, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine, (DSP4), or distilled water (control), 10–12 days before motor activity testing, and 6 h before testing all the mice were administered reserpine (10mg/kg), the monoamine-depleting agent. The interactive effects of (I) clonidine, the α2-adrenoceptor agonist, with the dopamine (DA) agonist, apomorphine, and the α2-antagonist, yohimbine, and (II) with either yohimbine or the α1-antagonist, prazosin, upon motor behaviour in activity test chambers were studied in reserpinized DSP4-treated and control mice. It was shown that apomorphine (3mg/kg) increased locomotor and total activity in both reserpinized DSP4-treated and control mice but the effect was attenuated in the DSP4 mice. Coadministration of clonidine (3 mg/kg) with apomorphine potentiated the effects of apomorphine on motor activity and this effect was enhanced markedly by DSP4 pretreatment. Yohimbine (10 mg/kg) antagonised the motor activity-stimulating effects of apomorphine in both DSP4-treated and control mice. Co-administration of clonidine with apomorphine, following yohimbine, restored motor activity levels to those obtained in the absence of yohimbine and this effect upon locomotor activity was enhanced by DSP4 pretreatment. The effects of clonidine on motor activity were enhanced by NA-denervation. Prazosin (3 mg/kg) enhanced the locomotor activity of both reserpinized DSP4-treated and control mice after the initial 30-mm period but was not affected by DSP4 treatment. Analysis of post-decapitation convulsions (PDCs) indicated loss of the reflex by DSP4 pretreatment. Reserpine pretreatment abolished the initial, exploratory phase (30 min) of motor activity. These results demonstrate interactions between NA and DA systems that may bear eventual relevance to neurologic disorders such as parkinsonism.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Reference
Archer, T., Cotic, T. and Jarbe, T.U.C. (1982) Attenuation of the context effect and lack of unconditioned stimulus preexposure effect in taste-aversion learning following treatment with DSP4, the selective noradrenaline neurotoxin. Behav. Neural Biol,35, 159–173.
Archer, T., Jonsson, G. and Ross, S.B. (1984) A parametric study of the effects of the noradrenaline neurotoxin DSP4 on avoidance acquisition and noradrenaline neurones in the CNS of the rat. Br.J. Pharmacol,82, 249–257.
Archer, T., Jonsson, G. and Ross, S.B. (1985) Active and passive avoidance following the administration of systemic DSP4, xylamine, or p-chloroamphetamine. Behav. Neural Biol,43, 238–249.
Archer, T., Fredriksson, A., Jonsson, G., Lewander, T., Mohammed, A.K., Ross, S.B. and Soderberg, U. (1986) Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat. Psychopharmacology (Berl.)88, 141–146.
Berlan, M., Rascol, O.et al. (1989) Alpha 2-adrenergic sensitivity in Parkinson’s disease. Clin. Neuropharmacol,12, 138–144.
Biaggioni, I., Robertson, R.M. and Robertson, D. (1994) Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J. Clin. Pharmacol,34, 418–423.
Carlsson, M. and Carlsson, A. (1989) Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J. Neural Transm.77, 65–71.
Carlsson, M. and Svensson, A. (1990a) Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol. Biochem. Behav.,36, 45–50.
Carlsson, M. and Svensson, A. (1990b) The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci.,47, 1729–1736.
Carlsson, M., Svensson, A. and Carlsson, A. (1991) Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice. Naunyn-Schmiedeberg’s Arch. Pharmacol,343, 568–573.
Cash, R., Ruberg, M.et al. (1984) Adrenergic receptors in Parkinson’s disease. Brain Res.,322, 269–275.
Chopin, P., Pellow, S. and File, S.E. (1986) The effects of yohimbine on exploratory and locomotor behaviour are attributable to its effects at noradrenaline and not at benzodiazepine receptors. Neuropharmacology,25, 53–57.
Cristofol, R.M. and Rodriquez-Farre, E. (1991) Differential presynaptic effects of hexachlorocyclohexane isomers on noradrenaline release in cerebral cortex. Life Sci.,49, 1111–1119.
Dolphin, A.C., Jenner, P.et al. (1976) The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice. Pharmacol. Biochem. Behav.,4, 661–670.
Eshel, G., Ross, S.B. et al (1990) Alpha Kbut not alpha 2)-adrenoceptor agonists in combination with the dopamine D2 agonist quinpirole produce locomotor stimulation in dopamine-depleted mice. Pharmacol. Toxicol,67, 123–131.
Fornai, F., Bassi, L., Torracca, M.T., Alessandri, M.G., Scalori, V. and Corsini, G.U. (1996) Region- and neurotransmitter-dependent species and strain differences in DSP4-induced monoamine depletion in rodents. Neurodegeneration,5, 241–249.
Fornai, R, Alessandri, M.G., Torracca, M.T., Bassi, L. and Corsini, G.U. (1997) Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. J. Pharmacol. Exp. Ther.,283, 100–107.
Fornai, P., Alessandri, M.G., Torracca, M.T., Bassi, L., Scatori, V. and Corsini, G.U. (1998a) Noradrenergic modulation of methampetamine-induced striatal dopamine depletion. Ann NY Acad. Set.,844, 166–177.
Fornai, R, Bassi, L., Torracca, M.T., Alessandri, M.G., Scatori, V. and Corsini, G.U. (1998b) Regional- and neurotransmitter-dependent species and strain differences in DSP4-induced monoamine depletion in rodents. Neurodegeneration,5, 241–249.
Fornai, R, Giorgi, F.S., Alessandri, M.G., Giusiani, M. and Corsini, G.U. (1999) Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. J. Neurochem.,72, 777–784.
Fredriksson, A. and Archer, T. (1994) MPTP-induced behavioural and biochemical deficits: A parametric analysis. J. Neural Transm.,7, 123–132.
Gobbi, M., Frittoli, E. and Mennini, T. (1990) The modulation of [3H]noradrenaline and [3H]serotonin release from rat brain synaptosomes is not mediated by the alpha 2B-adrenoceptor subtype. Naunyn Schmiedebergs Arch. Pharmacol.,342, 382–386.
Gobbi, M., Frittoli, E. and Mennini, T. (1993) Further studies on alpha 2-adrenoceptor subtypes involved in the modulation of [3H]noradrenaline and [3H]5-hydroxytryptamine release from rat brain cortex synaptosomes. J. Pharm. Pharmacol,45, 811–814.
Goldstein, M., Engel, J.et al. (1983) Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoceptor agonists. J. Neural Transm.,18(Suppl.) 257–263.
Henry, B., Crossman, A.R.et al. (1998) Characterization of enhanced behavioural responses to L-DOPA following repeated administration in the 6-hydroxydopaminelesioned rat model of Parkinson’s disease. Exp. Neurol.,151, 334–342.
Jonsson, G. (1980) Chemical neurotoxins as denervation tools in neurobiology. Annu. Rev. Neurosci.,3, 169–187.
Jonsson, G. and Hallman, H. (1982) Response of central monoamine neurons following an early neurotoxic lesion. Bibl. Anal,23, 76–92.
Jonsson, G., Hallman, H., Ponzio, F. and Ross, S.B. (1981) DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) — a useful denervation tool for central and peripheral noradrenaline neurons. Eur. J. Pharmacol.,72, 173–188.
Jonsson, G., Hallman, H. and Sundstrom, E. (1982) Effects of the noradrenaline neurotoxin DSP4 on the postnatal development of central noradrenaline neurons in the rat. Neuroscience,7, 2895–2907.
Kirk, R.E. (1995) Experimental Design. Procedures in Behavioural Science. Belmont CA, Brooks/Cole Inc.
Kiss, J.P, Zsilla, G., Mike, A., Zelles, T., Toth, E., Lajtha, A. and Vizi, E.S. (1995) Subtype-specificity of the presynaptic alpha 2-adrenoceptors modulating hippocampal norepinephrine release in rat. Brain Res.,674, 238–244.
Kostowski, W. and Malatynska, E. (1983) Antagonism of behavioural depression produced by clonidine in the mongolian gerbil: A potential screening test for antidepressant drugs. Psychopharmacology,79, 203–208.
Kunchandy, J. and Kulkarni, S.K. (1986) Reversal by alpha-2 agonists of diazepam withdrawal hyperactivity in rats. Psychopharmacology,90, 198–202.
Limberger, N., Spath, L. and Starke, K. (1991) Subclassification of the presynaptic alpha 2-autoreceptors in rabbit brain cortex. Br. J. Pharmacol,103, 1251–1255.
Marien, M., Briley, M. and Colpaert, R (1993) Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol,236, 487–489.
Mason, S.T. and Fibiger, H.C. (1979) Physiological function of descending noradrenaline projections to the spinal cord: Role in post-decapitation convulsions. Eur. J. Pharmacol,57, 29–34.
Meana, J.J., Herrerra-Marschitz, M., Goiny, M. and Silveira, R. (1997) Modulation of catecholamine release by alpha 2-adrenoceptors and Il-imidazoline receptors in the rat brain. Brain Res.,744, 216–226.
Musso, N.R., Gianrossi, R., Vergassola, C, Pende, A., Loverno, A., Galbariggi, G. and Lotti, G. (1992) Norepinephrine-induced plasma dopamine decrease in man: Pharmacological evidence of the involvement of alpha 2-adrenoceptors. J. Hypertens.,10, 1017–1023.
Nishikawa, T, Tanaka, M., Tsuda, A., Kohno, Y. and Nagasaki, N. (1983) Differential effects of clonidine on alpha 1- and alpha 2-adrenoceptors in footshock-induced jumping behavior. Eur. J. Pharmacol,88, 399–401.
Ogren, S.O., Archer, T. and Johansson, C. (1983) Evidence for a selective brain noradrenergic involvement in the locomotor stimulant effects of amphetamine in the rat. Neurosci. Lett.,43, 327–331.
Ogren, S.O. and Goldstein, M. (1994) Phencyclidine and dizocilpine-induced hyperlocomotion are differently mediated. Neuropsychopharmacology,11, 167–177.
Pucilowski, O., Trzaskowska, E., Kostowski, W. and Valzelli, L. (1987) Norepinephrine-mediated suppression of apomorphine-induced aggression and locomotor activity in the rat amygdala. Pharmacol Biochem. Behav.,26, 217–222.
Riekkinen, M., Kejonen, K.et al. (1998) Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson’s disease. Eur. J. Neurosci.,10, 1429–1435.
Roberts, D.C.S., Mason, S.T. and Fibiger, H.C. (1978) Selective depletion of spinal noradrenaline abolishes post-decapitation convulsions. Life Sci.,23, 2411–2414.
Ross, S.B. (1976) Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heart. Br. J. Pharmacol,58, 521–527.
Ross, S.B. and Renyi, L. (1976) On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on the active uptake of noradrenaline. J. Pharm. Pharmacol,28, 458–459.
Sanchez-Merino, J.A., Arribas, S., Arranz, A., Mann, J. and Balfagon, G. (1990) Regulation of noradrenaline release in human cerebral arteries via presynaptic alpha 2-adrenoceptors. Gen. Pharmacol,21, 859–862.
Schmidt, W.J. (1994) Behavioural effects of NMDA-receptor antagonists. J. Neural Transm.,43(Suppl.), 63–69.
Shoulson, Y. and Chase, T.N. (1976) Clonidine and the antiparkinsonian response to L-Dopa or piribedil. Neuropharmacology,15, 25–27.
Starr, M.S. and Starr, B.S. (1994) Potentiation of dopaminedependent locomotion by clonidine in reserpine-treated mice is restricted to D2 agonists. J. Neural Transm.: PD and D sect.,7, 133–142.
Tarsy, D., Parkes, J.D.,et al. (1975) Clonidine in Parkinson’s disease. Arch. Neurol,32, 134–136.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fredriksson, A., Archer, T. Effects of clonidine and α-adrenoceptor antagonists on motor activity in DSP4-treated mice II: Interactions with apomorphine. neurotox res 1, 249–259 (1999). https://doi.org/10.1007/BF03033255
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF03033255